AcuityMD, providers of a commercial platform for medical technology companies, has signed a multi-year contract with Dilon Technologies, a specialist in devices for breast cancer treatment and diagnosis.
Sk Elena Shutterstock
710369335
Ribbon representing breast cancer awareness
Dilon is using AcuityMD’s platform to accelerate identification and engagement of physicians treating surgical breast cancer patients to help stave off re-excision surgeries, which occur a surprising average of 20% of the time after a primary lumpectomy in the U.S. In the first month alone, AcuityMD’s platform enabled Dilon to research over 1,700 new surgeons and their clinical practices to quickly determine if their patients may benefit from MarginProbe.
Dilon’s MarginProbe, a technology for in-surgery, real-time breast cancer margin assessment, has shown a relative reduction of re-excision rates ranging from 25% up to 80%. It is the only FDA-approved, real-time margin assessment device specifically approved for breast surgery. Re-excision after breast-conserving surgery (BCS) is common, with high rates of re-operation associated with adverse outcomes and unnecessary complications. The goal is for all surfaces of an excised tumour to be cancer-free, but it can take pathology a week or more to make that assessment and can result in a second surgery. MarginProbe enables binary lumpectomy margin assessment while in the operating room to prevent additional surgery. With AcuityMD’s data-driven commercial platform, Dilon can identify the doctors and medical facilities whereas many patients as possible can benefit from its technologies.
George Makhoul, CEO of Dilon Technologies, said: "AcuityMD’s platform is a powerful targeting solution that allows us to deliver targeted solutions to physicians in order to improve their outcomes. It streamlines what would otherwise be a laborious process of identifying and determining how to prioritise the right surgeons with the relevant patients, with a goal of ultimately improving and potentially saving lives.”
Mike Monovoukas, CEO and co-founder of AcuityMD, added: “We are honoured to partner with Dilon Technologies to help advance the use of MarginProbe to help prevent re-excisions after lumpectomy surgery. Medtech companies spend as much as 40% of revenues on sales efforts. AcuityMD force-multiplies this investment through our industry-specific data platform and intuitive workflows. Our mission is to accelerate access to medical technologies. Empowering best-in-class technologies like Dilon’s MarginProbe is core to advancing our mission.”
